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Abstract 
 
Background: HLA supertypes are groups of functionally related alleles that present 
structurally similar antigens to the immune system. Despite many reports of HLA 
allele associations with dengue, there have to date been no studies of HLA supertype 
associations with disease.  
Objectives: To analyse HLA class I supertypes in hospitalised Thai children with 
acute dengue illness.                                                  
Methods: 762 patients and population-matched controls recruited predominantly in 
Bangkok were HLA-A and –B typed. HLA supertype frequencies were compared and 
tested for significant dengue disease associations using logistic regression analyses. 
Final multivariable models were built by conducting forward stepwise selection 
procedures.  
Results: In the final logistic regression model, the HLA-B44 supertype was protective 
against dengue hemorrhagic fever (DHF) in secondary infections (OR=0.46, 
95%CI=0.30-0.72), while the HLA-A02 supertype (OR=1.92, 95%CI=1.30-2.83) and 
the HLA-A01/03 supertype (OR=3.01, 95%CI=1.01-8.92) were associated with 
susceptibility to secondary dengue fever. The B07 supertype was associated with 
susceptibility to secondary DHF in the univariate analysis (OR=1.60, 95%CI=1.05-
2.46), whereas that was not retained in the final model.   
Conclusions:  As the HLA-B44 supertype is predicted to target conserved epitopes in 
dengue, our results suggest that B44 supertype-restricted immune responses to highly 
conserved regions of the dengue proteome may protect against secondary DHF.  
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Introduction 
 
In mainland southeast (SE) Asia all four dengue virus (DENV) serotypes are in 
seasonal circulation. Epidemiologic studies indicate DENV is amplifying in large 
population-dense and ethnically-diverse urban centres, such as Bangkok [1].  Here 
host immunologic pressure exerts positive selection on DENV [2], before the fittest 
serotypic strains spread from urban centres out in cyclical waves across the region 
into adjacent populations [1]. Clinical symptoms range from relatively benign dengue 
fever (DF) to the more severe dengue hemorrhagic fever (DHF) and dengue shock 
syndrome (DSS) [3,4], the latter two conditions associating with a more intense yet 
transient viremia [4,5].  Both primary and secondary DENV infections can induce 
clinical illness, but most patients with DHF are undergoing secondary infection with a 
virus serotype different from prior exposures [6]. Thus, immunologic priming to 
DENV influences disease expression, the level of viremia, and in turn the selection 
and transmission of the fittest viral strains.  
  
The immunologic function of class I human leukocyte antigens (HLA-A, B and C) is 
to present degraded fragments of endogenously synthesised virus antigens to CD8+ T 
cells of the adaptive immune response [7]. Some HLA class I molecules are also 
recognised by natural killer (NK) cells that have an innate ability to recognize and 
destroy infected cells [8]. HLA class I genes are extremely polymorphic and encode 
thousands of alleles, the majority of which are distinct structural and functional 
variants (see http://www.ebi.ac.uk/imgt/hla). Most polymorphism affects specific 
amino acids forming a series of pockets (A-F) which accommodate virus-derived 
peptides in the class I antigen-binding cleft, thus influencing the types of antigens 
 9 
presented to T cells [9]. Nevertheless, analysis of the protein sequence of antigens 
bound by different HLA class I molecules has identified groups of alleles or 
“supertypes”, with a common preference to present short peptides or antigen 
“supermotifs” sharing a similar structure [10].  
 
The frequency of HLA class I alleles and combinations of alleles in linkage 
disequilibrium or haplotypes varies considerably between different ethnic groups [11, 
12, see http://www.allelefrequencies.net]. Analysis of HLA class I allele and 
haplotype profiles in ethnic Thais has shown that this population is highly 
representative of the genetic admixture present in mainland SE Asians [12,13]. Case-
control HLA association studies with dengue disease have been performed in various 
cohorts identified in mainland SE Asia [14]. Collectively, nearly 1600 dengue patients 
have been HLA typed in Thailand [15, 16, 17], Vietnam [18, 19] and Malaysia [20]. 
Studies in ethnic Thais have indicated that a variety of HLA class I allele associations 
occur with secondary DENV infections, in particular with the HLA-B locus [16, 17] 
which is the most polymorphic in the human genome (see 
http://www.ebi.ac.uk/imgt/hla) and is also consistent with previous observations that 
HLA-B dominates the immune response to DENV and other RNA viruses [21-23].  
 
To date, there have been no reports of any HLA class I supertype associations with 
dengue disease. Nevertheless, bioinformatic modelling of the dengue proteome for 
predictive HLA class I binding antigen supermotifs has been performed [23]. In this 
study, we have HLA typed just over 750 ethnic Thai dengue patients and controls, and 
stratified the detected HLA class I alleles into their respective supertype groups. 
Using logistic regression analyses, we have identified a variety of HLA class I 
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supertype associations with dengue disease severity and susceptibility, and discuss 
our observations in the context of previous case control association studies and 
computational analyses of HLA supermotifs in the DENV proteome. 
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Materials and Methods 
 
Patients and controls. Unrelated hospitalised ethnic Thai children with serologically 
and virologically confirmed DENV infections between the ages of 3 and 14 years and 
weighing > 20 Kg were enrolled in Bangkok with fully informed consent between 
1994-2007, as previously described [16].  Clinical diagnoses of DF and DHF were 
assigned by an expert physician reviewer guided by the 1997 World Health 
Organisation (WHO) criteria [3].  277 DF and 163 DHF patients were available for 
HLA supertype analysis. 152 of these patients had been included in a previous HLA 
allele association study [16]. DHF was further classified into increasing grades of 
clinical severity, namely DHF-1, -2, -3 and -4 according to WHO criteria [3]. 
Serological responses to DENV were measured by both enzyme immunoassay and 
hemagglutination inhibition test. DENV serotypes (DENV-1, -2, -3 and -4) were 
identified by isolation in Toxorhynchites splendens mosquitoes or RT-PCR, as 
previously described [4, 5]. The infecting DENV serotype was determined in all but 7 
patients. Primary or secondary infections were defined on the basis of DENV-specific 
IgM:IgG serum antibody ratios and the titer of hemagglutination inhibition antibodies, 
according to WHO guidelines [3]. On this basis, 77/277 (27.8%) DF patients had 
primary infections, 200/277 (72.2%) DF patients had secondary infections, 13/163 
(8.0%) DHF patients had primary infections and 150/163 (92.0%) DHF patients had 
secondary infections. Two hundred and twenty-seven unrelated, ethnically and 
geographically matched, normal healthy Thai blood donors with no clinical history of 
autoimmune or malignant disease, whose families were known to have resided in the 
Bangkok metropolitan area for many generations, were used as population controls. 
However, the previous exposure to DENV in this control group was unknown.  A 
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further 95 unrelated  Thai patients (aged 3-14 years), composed of 51 secondary DF 
and 44 secondary DHF patients enrolled in Kamphaeng Phet (located 320km 
northwest of Bangkok) [4], were used to test and confirm the major HLA-B44 
supertype association identified in the Bangkok patients. All of the Kamphaeng Phet 
patients were included in a previous HLA allele association study [16]. No 
geographically-matched blood donor controls for the Kamphaeng Phet population 
were available. 
 
HLA-A and –B typing and supertype determination. Both serological phenotyping of 
fresh peripheral blood lymphocytes and molecular genotyping of full length genomic 
DNA, using PCR with sequence-specific primers and direct sequencing, were 
performed to HLA type patients and controls, as previously described 
[12,16,17,24,25]. This enabled confirmation of HLA class I allele expression and the 
exclusion of null or un-expressed alleles, before HLA-A and –B alleles were assigned 
according to Marsh et al [26] and supertypes according to Sidney et al [10]. HLA 
supertype frequencies (SF%) were determined using the following formula; SF (%) = 
n/N  x 100, where n = the number of individuals with a given supertype and N = the 
total number of individuals supertyped in each of the patient and control groups.  
 
Study design and statistical analysis. HLA-A and B SF’s were compared between 
each patient group (stratified for primary or secondary infections, disease severity, or 
the infecting DENV serotype) and the controls, and tested for associations using the 
Wald ChiSquare test for heterogeneity (2 x 2 contingency tables). P values < 0.05 
were considered significant. Correction of P values (Pc) for multiple comparisons 
(Bonferroni’s) and random supertype associations was dependent on the number and 
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type of comparisons made; namely the number of HLA-A (n=7) or -B (n=7) 
supertypes identified, combined with the number of patient and control group  
comparisons (n=7, primary DF versus controls, secondary DF versus controls, 
secondary DHF versus controls, all secondary infections versus controls, primary DF 
versus secondary DF, primary DF versus secondary DHF, secondary DF versus 
secondary DHF), which equates to 7 + 7 or 14 comparisons. Pc values < 0.05 were 
considered highly significant. Odds ratio (OR) with 95% confidence interval (CI) was 
used to assess the risk of either disease severity (OR with 95% CI >1.0) or protection 
(OR with 95% CI <1.0), associated with specific supertypes in either primary or 
secondary DENV infections. Previous (a priori) power calculations demonstrated that 
all patient and control groups were of sufficient size to achieve at least 80% power to 
detect HLA class I supertype differences of 11-21% (P< 0.05) [17], except for the 
primary DHF group (n=13) which was under powered and thus deemed too small for 
inclusion in the analysis. 
 
Multivariable regression models were also created to address the adjusted relationship 
between the clinical outcome of primary or secondary DENV and HLA class I 
supertype. Dengue infection status was classified into three clinical types (primary 
DF, secondary DF, and secondary DHF) and the relationship between risk of each 
clinical phenotype versus no disease (control) and HLA supertype was quantified 
using three separate logistic regressions. A forward stepwise selection procedure was 
performed to select each final multivariable model. All HLA class I supertypes were 
evaluated for inclusion in the multivariable model and retained if the P-value for an 
HLA supertype was <0.05. In order to assess whether the presence of one HLA 
supertype modified the relationship between another HLA supertype and risk of 
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specific dengue clinical outcomes, two-way interaction terms were tested for 
supertypes retained in the final model.  
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Results 
 
HLA-A supertypes. Our analysis of a Bangkok cohort of hospitalised paediatric  
dengue patients revealed a moderately significant association between the A02 
supertype and susceptibility to secondary DF and DHF, compared to the ethnically 
and geographically matched controls (Table 1). The preferred supermotif amino-acids 
held in the B and F pockets of the HLA class I antigen binding clefts of  A02 
supertype alleles, together with the A02 supertype alleles identified in our Thai cohort 
are also given in Table 1.  
 
HLA-B supertypes. In the equivalent analysis of HLA-B supertypes we detected 
another modest association between the B07 supertype and susceptibility to DHF in 
patients with secondary infections in Bangkok (Table 2). By contrast, the most 
significant association detected was with the B44 supertype and protection against 
developing severe DHF in secondary DENV infections, when compared to secondary 
DF patients and the controls (Pc < 0.05, Table 2). This association was tested in a 
second cohort of hospitalised Thai children with DENV infections identified in a 
geographically distinct region (Kamphaeng Phet, Thailand). The frequency of the B44 
supertype in Kamphaeng Phet secondary DHF (12/44, 27.3%) was also significantly 
reduced compared to secondary DF (24/51, 47.1%) in the same location (Wald Chi 
Square = 3.9, P = 0.0497, OR = 0.422, 95% CI 0.178-0.999).  
 
Logistic regression model. To investigate whether the evaluated HLA class I 
supertypes were related to either increased or decreased risk of primary/secondary DF 
or secondary DHF versus controls, logistic regression models were built (Table 3). 
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The primary DF model did not retain any significant supertype associations. 
However, the secondary DF model showed that A02 (OR = 1.92; P = 0.0011) and 
A01/A03 (OR = 3.01; P = 0.0474) supertypes were related to increased risk of 
secondary DF. The secondary DHF model demonstrated that the B44 supertype was 
related to decreased risk of secondary DHF (OR = 0.46; P = 0.0007). Separate models 
predicting secondary DF that included two-way interactions between A02 with 
A01/A03, A02 with B44, B07 with B44, and A01/A03 with B44, did not demonstrate 
significant interactions between these HLA class I supertype combinations, 
suggesting the presence of one did not significantly modify or change the relationship 
of the other supertype to secondary DF and DHF.   
 
B44 supertype protects against secondary DHF with all four DENV serotypes.   
Stratification for the known infecting DENV serotype indicated that the B44 
supertype was reduced in frequency in secondary DHF patients infected with any of 
the four serotypes (Table 4). This trend reached significance only in the DENV-1 
secondary infection group, which was the largest of the stratified groups (Table 4).  
 
B44 supertype protects against the most severe forms of DHF. Our analysis of 
Bangkok DHF patients stratified for increasing disease severity according to WHO 
classification of DHF grades 1, 2, 3 and 4 [3], indicated that the B44 supertype 
associates with protection against the more severe forms of DHF-2 and DHF-3/4 
(Table 5).  The most frequent B44 supertype-related alleles in our Thai cohort were 
HLA-B*40, B*18 and B*44, which were all relatively reduced in frequency in the 
secondary DHF patients (13.0%, 6.5% and 5.2%, respectively) compared to the 
equivalent antigen or phenotype frequencies in the controls (21.1%, 11.5% and 
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11.9%, respectively). This indicates that the B44 supertype associations described in 
Tables 2-5 are not due to relatively increased or decreased frequencies of any 
particular B44-related allele. 
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Discussion 
 
The largest HLA gene association studies with dengue have been performed in 
mainland SE Asian populations [reviewed in 14]. A variety of HLA-A and –B locus 
alleles have been reported to associate with protection or susceptibility to various 
clinical manifestations of DENV infection. Some of these associations have been 
consistent across Thai [15, 16, 17], Vietnamese [18, 19] and Malaysian populations 
[20], while other associations have been either target population- or DENV serotype-
specific. Such intra-regional differences in HLA associations with dengue may reflect 
the cyclical dynamics of distinct epidemic foci in the most population-dense urban 
centres such as Bangkok and Ho Chi Minh City that are not necessarily in the same or 
synchronized DENV transmission zones. Moreover, given the genetic similarity of 
ethnic Thais and Vietnamese in terms of their HLA allele profiles [12, 13, see 
http://www.allelefrequencies.net], any apparent regional differences of HLA 
associations with dengue may also reflect variations in historic immunologic priming 
to disparate DENV serotypes. Nevertheless, HLA class I allele associations have been 
reported in a variety of other populations in south Asia and the Americas [reviewed in 
14], which indicates that the clinical outcome of secondary exposure to DENV is at 
least in part mediated by T and NK cell-driven immune responses restricted by some 
HLA alleles. 
 
Bioinformatic scanning of the DENV proteome for HLA binding antigen supermotifs 
has predicted that most class I supertypes target predominantly non-conserved regions 
of the virus [23]. Cross-reactive partial immunity to previously unseen DENV  
serotypes is a recognised feature of the T cell response to DENV in secondary 
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infections [27], and may relate to HLA class I presentation of DENV epitopes that are 
not conserved across all four DENV serotypes. By contrast, the B44 supertype is 
predicted to target conserved regions of the DENV proteome [23]. In particular HLA-
B*40:01 and B*18:01, which are relatively common B44 supertype alleles in ethnic 
Thais [28, see http://www.allelefrequencies.net], are considered most efficient at 
targeting conserved regions across the proteomes of all four DENV serotypes [23].  
HLA-B*40 has also been associated with relatively high magnitude T cell responses 
to DENV in Sri Lankans (22).  Thus, the protective associations we describe in Tables 
2-5 may reflect HLA-B44 supertype-restricted T cell responses in immunologically 
primed patients targeting highly conserved DENV proteins and effectively reducing 
the chance of severe complications of secondary DENV infections arising. Reduced 
frequencies of HLA-B44 supertype-related alleles have also been reported in 
Malaysian DHF patients [20]. Moreover, given that the HLA class I supertypes in our 
patient groups were compared against the equivalent supertype frequencies in the 
ethnically and geographically matched urban population controls that are most likely 
to have had historic exposure to DENV, the relative protective effect of the B44 
supertype may even be stronger if compared against subclinical or asymptomatic 
controls.  
 
The concept of HLA supertypes is based on extensive information derived from either 
peptide binding studies to different HLA class I allelic products [10,29] or from 
sequencing natural HLA class I ligands by mass spectrometry [30]. Some 
discrepancies exist between these two approaches in defining the precise specificities 
of the preferred peptides recognised by different class I supertypes. Nevertheless, both 
methods have effectively confirmed that all B44 supertype alleles share a common 
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preference for antigenic supermotifs with a negatively charged amino acid (mostly 
Glu) in the first anchor position (pos 2) which binds the B-pocket, and a variety of 
hydrophobic residues at the C-terminus of the antigenic peptides (pos 9/10, see Table 
2) which bind the F-pocket of the class I antigen binding groove [9,10,29,30].  
Bioinformatic algorithms utilising this information together with other computational 
tools that predict intracellular peptide cleavage and antigen transport efficiency, have 
been used to screen conserved DENV protein sequences and identify putative B44 
supermotifs [23,31]. For example, the DENV NS3 protein which has protease and 
helicase functions is relatively rich in acidic or negatively charged amino acids [32]. 
Bioinformatic screening of NS3 for HLA class I supermotifs has revealed a 13-mer 
peptide (256-EIVDLMCHATFT-267) that is highly conserved across DENV-1, -2, -3 
and -4 serotypes [31]. This pan-serotype DENV peptide (NS3 256-267) contains at 
least 2 potential B44 supermotifs (Asp256 with Ala264, and Glu259 with Phe266). 
DENV NS3 256-267 is also predicted to contain other HLA class I and II supermotifs 
[31], and was originally shown to be recognized by a serotype cross-reactive HLA-
DP-restricted CD4 T cell clone [33], making it an attractive potential candidate for 
inclusion in future vaccines. 
 
Our observation that the A02 supertype is significantly increased in both secondary 
DF and DHF patients compared to geographically and ethnically-matched controls 
(Table 1), is consistent with other studies conducted at different time points in 
Bangkok [15], which has the largest urban population exposed to DENV in mainland 
SE Asia. The A02 supertype is largely composed of HLA-A*02 related alleles [10] of 
which 456 variants have been identified worldwide [see 
http://www.ebi.ac.uk/imgt/hla and http://www.allelefrequencies.net].  Most of the 
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polymorphism that defines HLA-A*02 alleles is focused on the pockets of the class I 
peptide binding groove.  Such variation is likely to restrict which peptides are 
preferentially bound and affect the subsequent antigen-specific immune responses 
invoked, as different HLA*02 variants have been shown to correlate with either 
secondary DF or DHF [16]. Bioinformatic modelling of the DENV  proteome has also 
predicted the A02 supertype preferentially binds variable sequences of the proteome 
that are not conserved between DENV serotypes [23], which would suggest that in 
immunologically primed individuals A02-restricted immune responses to disparate 
DENV serotypes are less able to control viral replication. 
 
The A24 supertype is composed of just HLA-A*24 related alleles [10], some of which 
have been associated with DHF and DSS in Vietnamese populations identified within 
or near to Ho Chi Minh city [18,19], the second largest urban epicentre of DENV 
transmission in mainland SE Asia. The A24 supertype is also reputed to target 
variable sequences of the DENV proteome that are not conserved between DENV 
serotypes [23]. In ethnic Thais HLA-A*24 alleles and the A24 supertype are 
increased in frequency in secondary DHF patients relative to secondary DF and 
controls, although these are trends rather than replicated associations reaching 
statistical significance [16] (Table 1). Similarly, the B07 supertype is significantly 
associated with susceptibility to secondary DHF (Table 2). However, this effect may 
be due to the presence of HLA-B*51 alleles in the B07 supertype which we have 
previously shown to associate with DHF in ethnic Thais [16], but did not retain 
significance with the final model (Table 3). By contrast, our logistic regression model 
did reveal an association between the relatively rare A01/A03 supertype and 
protection against secondary DHF (Table 3), which was not identified in our 
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univariate analysis (Table 1). The A01/A03 supertype does have subtle differences in 
its preferred antigenic supermotifs presented, and is represented by just the HLA-
A*30 allele in ethnic Thais (Table 1). 
 
A complex picture is emerging of the association of immune response genes and the 
role of their products in determining disease outcome of DENV infection, particularly 
after secondary exposures in immunologically primed individuals. Specific HLA class 
I alleles [15-20], extended haplotypes encoding specific combinations HLA class I 
and II alleles [17], cytokine gene polymorphisms [17], MHC class I chain-related 
(MIC) gene deletions [17], and now functionally-defined HLA class I supertypes 
(Tables 1, 2, 3 and 5), all associate with various aspects of disease outcome after 
DENV exposure. This suggests that there is most likely a major concentration of 
genes in the human MHC that influence dengue disease expression. Our study 
complements previous bioinformatic predictions on the relative immunogenicity of 
the DENV proteome by revealing in a major urban transmission zone that the B44 
supertype, which is predicted to target immune epitopes highly conserved across all 
DENV serotypes [23], is protective against the most severe consequences of 
secondary DENV infection (Table 4).  Taken together, these data suggest that 
vaccines designed to replicate and enhance B44 supertype-driven immune responses 
to DENV may induce protection against severe disease. 
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Table 1. HLA-A supertype frequencies in Bangkok Thai dengue patients and controls  
 
 
Supertype Frequency (SF%) 
 
Primary 
Infection 
Secondary 
Infection 
Control 
 
HLA 
class I 
Super- 
type 
HLA-A  
locus 
alleles 
in Thais 
Recognised supermotif in target antigens 
 
 
DF 
N=77 
 
n = 
(SF) 
DF 
N=200 
 
n = 
(SF)  
DHF 
N=150 
 
n = 
(SF)  
 
N=227 
 
n = 
(SF)  
A01 A*01 
A*26 
A*32 
Pos 2:  Small aliphatic (Ala, Thr, Ser, 
Val, Leu, Iso, Met, Gln) 
 
Pos 9/10: Aromatic and large 
hydrophobic (Phe, Trp, Tyr, Leu, Iso, 
Met) 
7 
(9%) 
11 
(6%) 
14 
(9%) 
23 
(10%) 
A02 A*02 Pos 2: Small aliphatic (Ala, Thr, Ser, 
Val, Leu, Iso, Met, Gln) 
 
Pos 9/10: Aliphatic and small 
hydrophobic (Leu, Iso, Val, Met, Gln, 
Ala)  
36 
(47%) 
 
105 
(53%) 
*A,*C 
75 
(50%) 
*B,*C 
85 
(37%) 
*A,*B, 
*C 
A03 A*03 
A*11 
A*31 
A*33 
Pos 2: :  Small aliphatic (Ala, Thr, Ser, 
Val, Leu, Iso, Met, Gln) 
 
Pos 9/10: Basic (Arg, His, Lys) 
57 
(74%) 
149 
(75%) 
99 
(66%) 
170 
(75%) 
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A24 A*24 Pos 2: Aromatic and aliphatic (Phe, Trp, 
Tyr, Leu, Iso, Val, Met, Gln) 
 
Pos 9/10: Aromatic, aliphatic and  
hydrophobic  (Phe, Try, Tyr, Leu, Ile, 
Met, Val, Ala) 
32 
(42%) 
65 
(33%) 
63 
(42%) 
82 
(36%) 
A01/ 
A03 
A*30 Pos 2: Small and aliphatic (Ala, Thr, 
Ser, Val, Leu, Iso, Met, Gln) 
 
Pos 9/10: Aromatic and basic (Tyr, Arg, 
Lys) 
1 
(1%) 
11 
(6%) 
4 
(3%) 
5 
(2%) 
A01/ 
A24 
A*29 Pos 2: Small, aliphatic and aromatic 
(Ala, Ser, Thr, Val, Leu, Ile, Met, Gln, 
Phe, Trp, Tyr) 
 
Pos 9/10: Aromatic and large 
hydrophobic (Phe, Trp, Tyr, Leu, Iso, 
Met) 
- 3 
(2%) 
3 
(2%) 
3 
(1%) 
UC A*34 Unknown  2 
(3%) 
4 
(2%) 
2 
(1%) 
3 
(1%) 
Wald Chi Square (WCSq) P= Pc= OR 95%CI 
*A A2 SF% in secondary DF infections vs controls, 
WCSq=9.7 
0.0019 0.0266 1.85 1.26 - 2.72 
*B A2 SF% in secondary DHF infections vs controls, 
WCSq=5.8 
0.0161 0.2254 1.67 1.10 - 2.54 
*C A2 SF% in all secondary infections (DF and DHF) vs 
controls, WCSq=10.8 
0.0010 0.0140 1.77 1.26 - 2.49 
 
HLA-A supertypes were designated according to Sidney et al [10] and are given 
together with their known target antigen supermotifs. HLA-A alleles detected in ethnic 
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Thais (patients and controls) and known to be in defined supertype groups [10], are as 
given. The 2-digit HLA allele designations indicate that all related class I alleles 
detected in the Thai population [28] fall within the defined supertype group. Within the 
respective supermotifs the amino-acid at position 2 (pos 2) binds to the B pocket, and 
amino-acids at pos 9 or 10 bind specifically to the F pocket of the HLA class I antigen-
binding groove [9,10]. N = total number of individuals in either patient or control 
groups, n = number of patients or controls with given HLA-A supertype. HLA-A class 
I supertype frequencies (SF) are given in parentheses and expressed as a relative 
percentage of the respective patient and control groups. SF showing significant 
differences between patient and control groups is indicated by an asterisk. Wald Chi 
Square, P values, Bonferroni’s corrected P values (Pc), Odds Ratio (OR) and 95% 
Confidence Interval (CI) are given in the last 4 rows. Significant P and Pc values, OR 
and 95% CI are given in bold. Pc for *A, *B, *C = P x 14 (7 supertypes + 7 patient 
group and control comparisons). 13 patients were identified with primary DHF but 
were excluded from the supertype analysis due to the relatively low numbers and lack 
of statistical power in testing for associations in this group (see Materials and 
Methods).  
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Table 2. HLA-B supertype frequencies in Bangkok Thai dengue patients and controls 
 
 
Supertype Frequency (SF%) 
 
Primary 
Infection 
Secondary 
Infection 
Control 
 
HLA 
class I 
Super- 
type 
HLA-B  
locus 
alleles 
in Thais 
 Recognised supermotif in target 
antigens 
 
 
DF 
N=77 
 
n = 
(SF)  
DF 
N=200 
 
n = 
(SF)  
DHF 
N=150 
 
n = 
(SF)  
 
N=227 
 
n = 
(SF)  
B07 B*07 
B*35 
B*51 
B*54 
B*55 
B*56 
B*67 
Pos 2: Proline 
 
Pos 9/10: Aromatic, aliphatic and  
hydrophobic  (Phe, Try, Tyr, Leu, Ile, 
Met, Val, Ala)  
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 (35%) 
76 
(38%) 
*B 
64 
(43%) 
*A,*B 
72 
(32%) 
*A,*B 
B08 B*08 Pos 2: undefined 
 
Pos 9/10: Aromatic, aliphatic and  
hydrophobic  (Phe, Try, Tyr, Leu, Ile, 
Met, Val, Ala) 
- 2  
(1%) 
- 3 
(1%) 
B27 B*27 Pos 2: Basic (Arg, His, Lys) 13 50 35 48 
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B*38 
B*39 
B*48 
 
Pos 9/10: Aromatic, aliphatic, basic and  
hydrophobic  (Phe, Try, Trp, Leu, Ile, 
Met, Arg, His, Lys, Val, Ala) 
 
 (17%) (25%) (23%) (21%) 
B44 B*18 
B*37 
B*40 
B*44 
B*50 
Pos 2: Acidic (Asp, Glu) 
 
Pos 9/10: Aromatic, aliphatic and 
hydrophobic  (Phe, Trp, Tyr, Leu, Ile, 
Val, Met, Gln, Ala) 
29 
 (38%) 
 
80 
(40%) 
*C,*E 
40 
(27%) 
*C,*D, 
*E 
 
 
100 
(44%) 
*D,*E 
B58 B*15:17 
B*57 
B*58 
Pos 2: Small (Ala, Ser, Thr) 
 
Pos 9/10: Aromatic, aliphatic and 
hydrophobic  (Phe, Trp, Tyr, Leu, Ile, 
Val, Met, Gln, Ala) 
12  
(16%) 
24 
(12%) 
28 
(19%) 
40 
(18%) 
B62 B*15:01 
B*15:02 
B*15:12 
B*15:13 
B*15:25 
B*46 
B*52 
Pos 2: Aliphatic (Leu, Iso, Val, Met, 
Gln) 
 
Pos 9/10: Aromatic, aliphatic and 
hydrophobic  (Phe, Trp, Tyr, Leu, Ile, 
Val, Met, Gln, Ala) 
 
43 
(56%) 
95 
(48%) 
77 
(51%) 
121 
(53%) 
UC B*13 
B*15:21 
B*15:27 
B*15:32 
 
Unconfirmed 13 
(17%) 
36 
(18%) 
24 
(16%) 
31 
  (14%) 
Wald Chi Square (WCSq) P= Pc= OR 95% CI 
*A B07 SF%  in secondary DHF infections vs controls, 0.0307 0.4298 1.60 1.05 - 2.46 
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WCSq = 4.7  
*B  B07 SF% in all secondary infections (DF and DHF) vs 
controls, WCSq = 4.0 
0.0442 0.6188 1.44 1.01 – 2.04 
*C B44 SF% in secondary DHF vs secondary DF infections, 
WCSq = 6.7 
0.0097 0.1358 0.55 0.35 - 0.86 
*D B44 SF% in secondary DHF vs controls, WCSq = 11.5 0.0007 0.0098 0.46 0.30 - 0.72 
*E B44 SF% in all secondary infections (DF and DHF) vs 
controls, WCSq = 5.5 
0.0185 0.2590 0.66 0.47 - 0.93 
 
HLA-B supertypes were designated according to Sidney et al [10] and are given 
together with their known target antigen supermotifs. HLA-B alleles detected in ethnic 
Thais and known to be in defined supertype groups [10], are as given. The 2-digit HLA 
allele designations indicate that all related class I alleles detected in the Thai 
population [28] fall within the defined supertype group. Within the respective 
supermotifs the amino-acid at pos 2 binds the B pocket, and amino-acids at pos 9 or 10 
bind specifically to the F pocket of the HLA class I antigen-binding groove [9,10]. N = 
total number of individuals in either patient or control groups, n = number of patients 
or controls with given HLA-B supertype. HLA-B class I supertype frequencies (SF) 
are given in parentheses and expressed as a relative percentage of the respective patient 
and control groups. SF showing significant differences between patient and control 
groups are indicated by an asterisk. Wald Chi Square, P values, Bonferroni’s corrected 
P values (Pc), Odds Ratio (OR) and 95% Confidence Interval (CI) are given in the last 
6 rows. Significant P and Pc values, OR and 95% CI are given in bold. Pc for *A, *B, 
*C, *D and *E = P x 14 (7 supertypes + 7 patient group and control comparisons).  13 
patients were identified with primary DHF but were excluded from the supertype 
analysis due to the relatively low numbers and lack of statistical power in testing for 
associations in this group (see Materials and Methods).  
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Table 3. Logistic regression models for HLA class I supertype associations with 
dengue virus infection 
  
Secondary DENV 
Infection 
HLA class I Supertype 
OR 
versus 
Controls 
95% CI P value 
A02 1.92 1.30 – 2.83 0.0011 
DF 
A01/A03 3.01 1.01 – 8.92 0.0474 
DHF B44 0.46 0.30 – 0.72 0.0007 
OR = Odds Ratio; 95% CI = 95% Confidence Interval. 
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Table 4. Logistic regression analysis of HLA-B44 supertype frequencies in secondary 
DENV-1, DENV-2, DENV-3 or DENV-4 infections in Bangkok Thais 
  
DENV serotype identified in secondary infections   
DENV-1 DENV-2 DENV-3 DENV-4 
  
  
DF 
N=74 
  
n = 
(SF) 
DHF 
N= 50 
  
n = 
(SF) 
DF 
N=40  
  
n = 
(SF) 
DHF 
N=39 
  
n = 
(SF) 
DF 
N=42 
  
n = 
(SF) 
DHF 
N=37 
  
n = 
(SF) 
DF 
N=42  
  
n = 
(SF) 
DHF 
N=21 
  
n = 
(SF) 
Control  
  
N=227 
  
n = 
   (SF) 
HLA B44 Supertype 32 
(43%) 
12 
(24%) 
14 
(35%) 
11 
(28%) 
18 
(43%) 
11 
(30%) 
15 
(36%) 
5 
(24%) 
100 
(44%) 
OR (95%CI)  
Patient Groups versus 
Controls (ref)  
0.97 
(0.57- 
1.64) 
0.40 
(0.20- 
0.81)* 
0.68 
(0.34- 
1.38) 
0.50 
(0.24- 
1.05) 
0.95 
(0.49- 
1.85) 
0.54 
(0.25- 
1.14) 
0.71 
(0.36- 
1.40) 
0.40 
(0.14- 
1.12) 
ref 
Wald Chi Square 
derived P value  0.9031 0.0105 0.2877 0.0675 0.8862 0.1056 0.3172 0.0809 
 
OR (95%CI)  
DHF versus DF (ref) 
within given DENV 
serotype 
 
 ref 0.41 
(0.19- 
0.92)* 
 
ref 0.73 
(0.28- 
1.89) 
 
ref 0.56 
(0.22- 
1.43) 
 
ref 0.56 
(0.17- 
1.84) 
  
Wald Chi Square 
derived P value 
 
0.0300 
 
0.5168 
 
0.2291 
 
0.3419 
 
 
The HLA B44 supertype was designated according to Sidney et al [10] and the known 
target antigen supermotif is as given in Table 2. Secondary DF and DHF patients were 
stratified for infecting dengue virus serotype as described in Materials and Methods. 
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N = total number of individuals in each patient and control group, n = number of 
patients with HLA-B44 supertype. HLA-B44 supertype frequencies (SF) are given in 
parentheses and expressed as a relative percentage of the respective patient and 
control groups in row 1. The infecting virus serotype was not determined in two 
patients with secondary DF and three patients with secondary DHF (as given in Table 
2). Of these patients with an undetermined dengue serotype two had the B44 
supertype, one with secondary DF and the other with secondary DHF . Odds Ratios 
(OR) with 95% confidence interval (95% CI) were generated using multivariable 
logistic regression. OR (95%CI) generated for comparisons of SF in patient groups 
versus controls (ref) are given in row 2. OR (95%CI) generated for comparisons of SF 
in DHF versus DF (ref) in patients infected with the same DENV subtype are given in 
row 3.  * OR showing significant B44 SF differences between patient and control 
groups are indicated in bold and with an asterisk.  Significant Wald Chi Square 
derived P values (<0.05) are given in bold. 
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Table 5. Logistic regression analysis of HLA B44 supertype associations with severe 
secondary dengue infections in Bangkok Thais 
 
HLA-B44 Supertype Frequency (SF%) in patients with secondary 
dengue and controls  
  
 
 
Secondary  
DF 
  
N=200 
  
n = 
(SF) 
Secondary  
DHF-1 
  
N= 22 
  
n = 
(SF) 
Secondary  
DHF-2 
  
N= 96 
  
n = 
(SF) 
Secondary  
DHF-3/4 
  
N= 32 
  
n = 
(SF) 
  
Control  
  
  
N=227 
  
n = 
(SF) 
HLA B44 Supertype 80 
(40%) 
  
7 
(32%) 
28 
(29%) 
  
5 
(16%) 
  
100 
(44%) 
  
OR  
(95%CI) 
Patient Groups versus 
controls (ref) 
0.85 
 (0.58-1.25) 
0.59 
 (0.23-1.51) 
0.52  
(0.31- 0.87)* 
0.24  
(0.09-0.63)* 
 
 
Ref 
Wald Chi Square derived   
P value 0.3975 0.2727 0.0131 0.0041 
 
OR  
(95%CI) 
DHF versus DF (ref) 
 
Ref 0.70  
(0.27-1.79) 
0.62  
(0.37-1.04) 
0.28 
 (0.10-0.75)* 
  
Wald Chi Square derived   
P value 
 
0.4574 0.0711 0.0117 
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HLA-B44 supertypes were designated according to Sidney et al [10] and the known 
target antigen supermotif is as given in Table 2. Secondary DHF patients were 
stratified for disease severity into DHF-1, -2 and -3/4 groups as described in Materials 
and Methods. Only one patient in the DHF-3/4 group was defined as DHF-4. N = total 
number of individuals in each patient and control group, n = number of patients with 
HLA-B44 supertype. HLA-B44 supertype frequencies (SF) are given in parentheses 
and expressed as a relative percentage of the respective patient and control groups in 
row 1. Odds Ratios (OR) with 95% confidence interval (95% CI) were generated 
using multivariable logistic regression. OR (95%CI) generated for comparisons of SF 
in patient groups versus controls (ref) are given in row 2. OR (95% CI) generated for 
comparisons of SF in DHF versus DF (ref) are given in row 3. * OR showing 
significant B44 SF differences between patient and control groups are indicated in 
bold and with an asterisk.  Significant Wald Chi Square derived P values (<0.05) are 
given in bold. 
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